Business Card for Gregory Kelner, Ph.D. PMP:


Associate Director and Group
San Francisco, CA area
Email Avail: 3 Day Free Trial


1 Dna Way
South San Francisco, CA 94080

Tel: (650) 225-1000

Last updated on 2018-01-13


About Gregory Kelner, Ph.D. PMP:

Gregory Kelner, Ph.D. PMP works as an Associate Director and Group for Genentech, Inc. at San Francisco, CA. The company's webpage is http://www.gene.com. For email, phone number and executive profiles for Associate Director and Group and other executives of Genentech, Inc. at San Francisco, CA, check Genentech, Inc. at Joesdata.com. Not the Gregory Kelner, Ph.D. PMP you are looking for? Do a quick search in our website and find other people named Gregory Kelner, Ph.D. PMP.
Gregory Kelner, Ph.D. PMP's Work History:
Director and Secretary Board of Directors at Drug Discovery for Tropical Diseases
Chair of the 8th Annual Project Management Conference for the Drug and Device Industry at BioPharmaPM Network
Associate Director Program Management at Biogen Idec
Senior Program Manager at Biogen Idec
Project Manager at Biogen Idec
Adjunct Associate Professor at San Diego State University
Project Leader at Arena Pharmaceuticals
Senior Scientist at Neurocrine Biosciences
Post Doctoral Fellow at DNAX Research Institute.

Gregory Kelner, Ph.D. PMP's Education:
University of Minnesota Medical School
University of California
Santa Barbara.

Gregory Kelner, Ph.D. PMP's Co-workers:
As of January 15, 2021, Gregory Kelner, Ph.D. PMP has 1358 co-workers under the company name Genentech, Inc. at Joesdata.com.

About Genentech, Inc.:

Genentech, Inc. is located at 1 Dna Way , South San Francisco, CA 94080. It has over 10K employees. Its revenue is over $1B.

Company News:
2018-09-13 19:18:41
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
2018-09-13 17:30:39
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
2018-09-06 19:24:23
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
2018-08-30 17:30:48
Positive Phase III Results for Genentechs HEMLIBRA (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
2018-08-13 19:19:15
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
2018-08-13 17:30:37
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
2018-07-25 17:42:26
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
2018-07-25 17:31:17
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
2018-07-20 18:54:47
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimers Program at the Upcoming Alzheimer's Association International Conference (AAIC)
2018-07-20 17:30:51
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimers Program at the Upcoming Alzheimer's Association International Conference (AAIC)

People in the same industry: